The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality
Open accessAbstract
Breast cancer is a common malignancy with current biological therapies tailored to steroid hormone (ER, PR) and HER2 receptor status. Understanding the biological basis of resistance to current targeted therapies and the identification of new potential therapeutic targets is an ongoing challenge. The PI3K pathway is altered in a high proportion of breast cancers and may contribute to therapeutic resistance. We undertook an integrative study of mutational, copy number and expression analyses of key regulators of the PI3K pathway in a cohort of 292 invasive breast cancer patients with known treatment outcomes. The alterations identified in this cohort included PIK3CA mutations (12/168, i.e. 7%), PIK3CA copy number gain (28/209, i.e. 14%), PTEN loss (73/258, i.e. 28%) and AKT activation (62/258, i.e. 24%). Overall at least 1 parameter was altered in 72% (139/193) of primary breast cancers. PI3K pathway activation was significantly associated with ER negative (p = 0.0008) and PR negative (p = 0.006) status, high tumor grade (p = 0.032) and a “basal‐like” phenotype (p = 0.01), where 92% (25/27) of tumors had an altered pathway. In univariate analysis, PI3K pathway aberrations were associated with death from breast cancer; however, this relationship was not maintained in multivariate analysis. No association was identified between an activated pathway and outcome in tamoxifen‐ or chemotherapy‐treated patients. We concluded that >70% of breast cancers have an alteration in at least 1 component of the PI3K pathway and this might be exploited to therapeutic advantage especially in “basal‐like” cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Liang, J., & Slingerland, J. M. (2003) · Cell Cycle · doi:10.4161/cc.2.4.433 · Cited by 885
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Foulkes, W. D., Brunet, J.-S., Stefansson, I. M., Straume, O., Chappuis, P. O., Bégin, L. R., Hamel, N., Goffin, J. R., Wong, N., Trudel, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2970 · Cited by 363
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer
Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 294
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M. (2005) · The Journal of Pathology · doi:10.1002/path.1829 · Cited by 268
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228
Marty, B., Maire, V., Gravier, E., Rigaill, G., Vincent-Salomon, A., Kappler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216
PIK3CA mutations in breast cancer are associated with poor outcome
Li, S. Y., Rong, M., Grieu, F., & Iacopetta, B. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9048-0 · Cited by 207
Rojo, F., Najera, L., Lirola, J., Jiménez, J., Guzmán, M., Sabadell, M. D., Baselga, J., & Cajal, S. R. Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1560 · Cited by 205
Activation of PI3K/Akt signaling and hormone resistance in breast cancer
Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Morita, M., Kakeji, Y., Baba, H., & Maehara, Y. (2006) · Breast Cancer · doi:10.2325/jbcs.13.137 · Cited by 199
Barbareschi, M., Buttitta, F., Felicioni, L., Cotrupi, S., Barassi, F., Del Grammastro, M., Ferro, A., Dalla Palma, P., Galligioni, E., & Marchetti, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0266 · Cited by 193
Tokunaga, E., Kimura, Y., Oki, E., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., Baba, H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21358 · Cited by 177
The Akt pathway in human breast cancer: a tissue-array-based analysis
Bose, S., Chandran, S., Mirocha, J. M., & Bose, N. (2006) · Modern Pathology · doi:10.1038/modpathol.3800525 · Cited by 176
Panigrahi, A., Pinder, S., Chan, S., Paish, E., Robertson, J., & Ellis, I. (2004) · The Journal of Pathology · doi:10.1002/path.1611 · Cited by 164
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women
Maruyama, N., Miyoshi, Y., Taguchi, T., Tamaki, Y., Monden, M., & Noguchi, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0267 · Cited by 152
Carson, J. P., Kulik, G., & Weber, M. J. (1999) · PubMed · Cited by 144
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
丸山, 尚. (2009) · Cited by 119
Buttitta, F., Felicioni, L., Barassi, F., Martella, C., Paolizzi, D., Fresu, G., Salvatore, S., Cuccurullo, F., Mezzetti, A., Campani, D., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1908 · Cited by 103
Tsutsui, S., Inoue, H., Yasuda, K., Suzuki, K., Higashi, H., Era, S., & Mori, M. (2005) · Oncology · doi:10.1159/000086981 · Cited by 101
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Kita, D., Yonekawa, Y., Weller, M., & Ohgaki, H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0186-1 · Cited by 100
Millar, E. K. A., Dean, J. L., McNeil, C. M., O’Toole, S. A., Henshall, S. M., Tran, T. H., Lin, J., Quong, A. A., Comstock, C. E. S., Witkiewicz, A. K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.13 · Cited by 88
Self-citationNoh, W. C., Kim, Y. H., Kim, M. S., Koh, J. S., Kim, H., Moon, N. M., & Paik, N.-S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9746-x · Cited by 79
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
Ginestier, C., Adélaı̈de, J., Gonçalvès, A., Repellini, L., Sircoulomb, F., Letessier, A., Finetti, P., Geneix, J., Charafe‐Jauffret, E., Bertucci, F., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210528 · Cited by 69
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases
Akçakanat, A., Şahin, A. A., Shaye, A. N., Velasco, M. A. D., & Meric‐Bernstam, F. (2008) · Cancer · doi:10.1002/cncr.23456 · Cited by 64
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Liedtke, C., Cardone, L., Tordai, A., Yan, K., Gómez, H., Barajas-Figueroa, L. J., Hubbard, R. E., Valero, V., Souchon, E. A., Symmans, W. F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr1984 · Cited by 63
Jung, V., Kindich, R., Kamradt, J., Jung, M., Müller, M., Schulz, W. A., Engers, R., Unteregger, G., Stöckle, M., Zimmermann, R., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0165 · Cited by 60
Dourdin, N., Schade, B., Lesurf, R., Hallett, M. T., Munn, R. J., Cardiff, R. D., & Muller, W. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5727 · Cited by 55
de Crémoux, P., Tran‐Perennou, C., Brockdorff, B. L., Boudou, E., Br√ºnner, N., Magdel�nat, H., & Lykkesfeldt, A. E. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100409 · Cited by 51
Commentary on Essential roles of PI(3)K-p110β in cell growth, metabolism, and tumorigenesis
Huang, H. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.12.002 · Cited by 50
Millar, E. K. A., Anderson, L. R., McNeil, C. M., O'Toole, S. A., Pinese, M., Crea, P., Morey, A. L., Biankin, A. V., Henshall, S. M., Musgrove, E. A., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604809 · Cited by 41
Self-citationExon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
Lerma, E., Catasús, L., Gallardo, A., Peiró, G., Alonso, C., Aranda, I., Barnadas, A., & Prat, J. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0643-4 · Cited by 36
Lee, J. S., Kim, H. S., Kim, Y. B., Lee, M. C., Park, C. S., & Min, K. W. (2004) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200409000-00004 · Cited by 35
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
André, F., Nahta, R., Conforti, R., Boulet, T., Aziz, M., Yuan, L. X. H., Meslin, F., Spielmann, M., Tomasic, G., Pusztai, L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm429 · Cited by 34
Cited by
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 355
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
Endocrine resistance in breast cancer – An overview and update
Clarke, R., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 353
Metadata
- Authors
- López‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-11-04
- Volume
- 126
- Issue
- 5
- Pages
- 1121-1131
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2073308507
- Cited by
- 302
- References
- 50
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.